https://www.pharmaradar360.com/article/using-ai-to-close-the-post-market-design-loop-greenlight-guru-cb53504b2f3062c9Pharma Surgeen2026-06-22T11:40:35.000ZUsing AI to close the post-market design loop | Greenlight Guruhttps://www.pharmaradar360.com/article/les-hopitaux-universitaires-de-strasbourg-remportent-le-challenge-des-foulees-ec-bf6b779392b0daabPharma Surgeen2026-06-22T11:35:15.000ZLes Hôpitaux Universitaires de Strasbourg remportent le Challenge des Foulées éco-solidaires pour la deuxième année consécutivehttps://www.pharmaradar360.com/article/les-hus-informent-et-accompagnent-les-patients-atteints-d-un-cancer-du-rein-a901820ea576070dPharma Surgeen2026-06-22T11:32:58.000ZLes HUS informent et accompagnent les patients atteints d’un cancer du reinhttps://www.pharmaradar360.com/article/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfolio-9b2e7536a11549b2Pharma Surgeen2026-06-22T11:00:00.000ZAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfoliohttps://www.pharmaradar360.com/article/labcorp-announces-nationwide-availability-of-colosense-the-first-fda-approved-rn-068f3933db6b7cf8Pharma Surgeen2026-06-22T11:00:00.000ZLabcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Testhttps://www.pharmaradar360.com/article/hlth-europe-2026-enriching-the-patient-journey-with-health-technologies-9e826b27d27b1e0dPharma Surgeen2026-06-22T10:48:22.000ZHLTH Europe 2026: enriching the patient journey with health technologieshttps://www.pharmaradar360.com/article/merck-s-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atla-85af5c6c78bad7b8Pharma Surgeen2026-06-22T10:45:00.000ZMerck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)https://www.pharmaradar360.com/article/uk-mhra-sets-path-for-puberty-blocker-trial-to-continue-62b14910416be8b1Pharma Surgeen2026-06-22T10:44:08.000ZUK MHRA sets path for puberty blocker trial to continuehttps://www.pharmaradar360.com/article/moderna-s-mrna-flu-vaccine-passes-fda-adcom-review-underway-5cc6b2e1754d565cPharma Surgeen2026-06-22T10:43:25.000ZModerna’s mRNA flu vaccine passes FDA AdCom, review underwayhttps://www.pharmaradar360.com/article/kither-biotech-concludes-phase-i-study-of-kit2014-22007ca816480c6dPharma Surgeen2026-06-22T10:34:38.000ZKither Biotech concludes Phase I study of KIT2014https://www.pharmaradar360.com/article/post-marketing-oncology-studies-enabling-faster-recruitment-and-lower-costs-4e5922e109d7a80bPharma Surgeen2026-06-22T10:21:14.000ZPost-marketing oncology studies: Enabling faster recruitment and lower costshttps://www.pharmaradar360.com/article/post-marketing-oncology-studies-enabling-faster-recruitment-and-lower-costs-d21e482d9e74bdd7Pharma Surgeen2026-06-22T10:17:06.000ZPost-marketing oncology studies: Enabling faster recruitment and lower costshttps://www.pharmaradar360.com/article/the-benefits-and-challenges-of-100-percent-us-based-manufacturing-ce4903f826bc8aeaPharma Surgeen2026-06-22T10:00:00.000ZThe Benefits and Challenges of 100 Percent US-Based Manufacturinghttps://www.pharmaradar360.com/article/icon-selects-microsoft-as-a-preferred-technology-partner-to-power-ai-enabled-cli-6d62bb6d794b913dPharma Surgeen2026-06-22T09:53:36.000ZICON Selects Microsoft as a Preferred Technology Partner to Power AI-Enabled Clinical Developmenthttps://www.pharmaradar360.com/article/heidelberg-among-the-top-three-universities-in-germany-c0776f33e63073ecPharma Surgeen2026-06-22T09:52:53.000ZHeidelberg Among the “Top Three” Universities in Germanyhttps://www.pharmaradar360.com/article/congressional-budget-office-contends-provider-wins-undermining-no-surprises-act-4f643b550a354651Pharma Surgeen2026-06-22T09:51:35.000ZCongressional Budget Office contends provider wins undermining No Surprises Acthttps://www.pharmaradar360.com/article/world-refugee-day-showing-solidarity-with-refugees-in-south-africa-1c171c82a338e056Pharma Surgeen2026-06-22T09:14:19.000ZWorld Refugee Day: Showing solidarity with refugees in South Africahttps://www.pharmaradar360.com/article/la-adquisicion-de-rois-phoenix-marca-un-nuevo-hito-en-la-internacionalizacion-de-2fa01139f7d26eabPharma Surgeen2026-06-22T09:11:14.000ZLa adquisición de ROIS PHOENIX marca un nuevo hito en la internacionalización del negocio de fabricación a terceros de ROIShttps://www.pharmaradar360.com/article/the-evolution-of-the-adc-market-and-what-it-means-for-commercial-packaging-714a26e7f1767217Pharma Surgeen2026-06-22T09:03:42.000ZThe evolution of the ADC market – and what it means for commercial packaginghttps://www.pharmaradar360.com/article/sun-pharma-to-acquire-innovcare-lifesciences-for-28-7m-f87cae1880af8055Pharma Surgeen2026-06-22T09:03:35.000ZSun Pharma to acquire Innovcare Lifesciences for $28.7mhttps://www.pharmaradar360.com/article/women-living-with-ms-take-to-the-stage-in-powerful-showcase-7f459939722c5587Pharma Surgeen2026-06-22T09:03:17.000ZWomen living with MS take to the stage in powerful showcasehttps://www.pharmaradar360.com/article/does-drinking-juice-soda-during-childhood-increase-the-risk-of-high-blood-pressu-7ecd15e132fabe8ePharma Surgeen2026-06-22T09:00:00.000ZDoes drinking juice, soda during childhood increase the risk of high blood pressure?https://www.pharmaradar360.com/article/first-participant-receives-evategrel-in-curegene-s-trial-e95a1d08784001acPharma Surgeen2026-06-22T08:55:41.000ZFirst participant receives Evategrel in CureGene’s trialhttps://www.pharmaradar360.com/article/algae-microbots-take-aim-at-bladder-cancer-7c544810e644309fPharma Surgeen2026-06-22T08:51:26.000ZAlgae microbots take aim at bladder cancerhttps://www.pharmaradar360.com/article/post-covid-syndrom-blutwasche-zeigt-in-studie-keinen-nutzen-fur-betroffene-8aec8256c4d917c0Pharma Surgeen2026-06-22T08:31:45.000ZPost-Covid-Syndrom: Blutwäsche zeigt in Studie keinen Nutzen für Betroffenehttps://www.pharmaradar360.com/article/research-as-a-constant-balancing-act-between-opportunities-and-risks-f86e89733ba4237bPharma Surgeen2026-06-22T08:20:09.000ZResearch as a Constant Balancing Act between Opportunities and Riskshttps://www.pharmaradar360.com/article/muttermilch-fur-fruhgeborene-7f4dfe8063e439dePharma Surgeen2026-06-22T08:13:10.000ZMuttermilch für Frühgeborenehttps://www.pharmaradar360.com/article/acuerdos-aprobados-y-votaciones-6a9c9d85a3a28004Pharma Surgeen2026-06-22T08:11:47.000ZAcuerdos aprobados y votacioneshttps://www.pharmaradar360.com/article/japan-approves-sanofi-s-sarclisa-combo-for-mm-treatment-725956350ad515e9Pharma Surgeen2026-06-22T08:01:58.000ZJapan approves Sanofi’s Sarclisa combo for MM treatmenthttps://www.pharmaradar360.com/article/ai-tool-reveals-hidden-organ-damage-caused-by-high-blood-pressure-d26a1ebe0f5d8484Pharma Surgeen2026-06-22T08:00:42.000ZAI tool reveals hidden organ damage caused by high blood pressurehttps://www.pharmaradar360.com/article/hydration-break-advertising-signals-a-lasting-shift-in-global-football-2c4fe8a51b6eea74Pharma Surgeen2026-06-22T08:00:00.000ZHydration break advertising signals a lasting shift in global footballhttps://www.pharmaradar360.com/article/2026-3-4-7-24-20dc904f5aeba21bPharma Surgeen2026-06-22T07:41:22.000Z2026年度 第3回・第4回 臨床研究教育セミナー開催のお知らせ（7/24開催）https://www.pharmaradar360.com/article/information-about-the-criminal-offence-committed-by-a-former-employee-of-the-uni-ee060b2d6ee29a14Pharma Surgeen2026-06-22T07:08:00.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/holland-chair-spurs-innovation-in-public-health-1e60892ce4c00a6ePharma Surgeen2026-06-22T07:00:00.000ZHolland chair spurs innovation in public healthhttps://www.pharmaradar360.com/article/between-heat-exhaustion-and-heat-stroke-what-you-need-to-know-b5fac13ff19ea0b9Pharma Surgeen2026-06-22T07:00:00.000ZBetween Heat Exhaustion and Heat Stroke: What You Need to Knowhttps://www.pharmaradar360.com/article/unmc-team-publishes-review-article-on-hantavirus-6569e837d3eb2a4dPharma Surgeen2026-06-22T06:58:00.000ZUNMC team publishes review article on Hantavirushttps://www.pharmaradar360.com/article/new-faculty-spotlight-logan-kludt-lawrence-dds-a684a1a813941e79Pharma Surgeen2026-06-22T06:56:00.000ZNew faculty spotlight: Logan Kludt Lawrence, DDShttps://www.pharmaradar360.com/article/powys-teaching-health-board-goes-live-with-better-epma-96a8e50e9fe3277aPharma Surgeen2026-06-22T06:30:39.000ZPowys Teaching Health Board goes live with Better ePMAhttps://www.pharmaradar360.com/article/skydda-dig-infor-resan-se-over-ditt-vaccinationsskydd-e596a86c455487dcPharma Surgeen2026-06-22T06:16:52.000ZSkydda dig inför resan – se över ditt vaccinationsskyddhttps://www.pharmaradar360.com/article/year-to-date-business-update-ahead-of-annual-general-meeting-40631478ea36b1eaPharma Surgeen2026-06-22T06:02:08.000ZYear-to-date business update ahead of Annual General Meetinghttps://www.pharmaradar360.com/article/volontariato-22-06-cieli-azzurri-concerto-jazz-per-i-bambini-del-policlinico-di-0447a968f8ee1696Pharma Surgeen2026-06-22T06:00:00.000Z#VOLONTARIATO [22.06] Cieli Azzurri, concerto jazz per i bambini del Policlinico di Milanohttps://www.pharmaradar360.com/article/comment-la-production-hepatique-d-epo-s-eteint-a-la-naissance-24dfced76484851fPharma Surgeen2026-06-22T06:00:00.000ZComment la production hépatique d’EPO s’éteint à la naissancehttps://www.pharmaradar360.com/article/dermatite-eczema-e-scottatura-l-abc-delle-irritazioni-della-pelle-4f84152ee8e319fdPharma Surgeen2026-06-22T05:58:00.000ZDermatite, eczema e scottatura: l'ABC delle irritazioni della pellehttps://www.pharmaradar360.com/article/2027-tour-de-cure-mid-atlantic-cbdfd4a4a883db5cPharma Surgeen2026-06-22T05:14:19.000Z2027 Tour de Cure®: Mid-Atlantichttps://www.pharmaradar360.com/article/2027-tour-de-cure-florida-0fa5e13cec6c739dPharma Surgeen2026-06-22T05:14:19.000Z2027 Tour de Cure®: Floridahttps://www.pharmaradar360.com/article/2027-tour-de-cure-arizona-0efea63f938482ccPharma Surgeen2026-06-22T05:14:19.000Z2027 Tour de Cure®: Arizonahttps://www.pharmaradar360.com/article/2027-step-out-walk-tennessee-1800ca0610479d64Pharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Tennesseehttps://www.pharmaradar360.com/article/2027-step-out-walk-tampa-d991751ab8ce02aePharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Tampahttps://www.pharmaradar360.com/article/2027-step-out-walk-north-texas-62b162c70317fadaPharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: North Texashttps://www.pharmaradar360.com/article/2027-step-out-walk-hawaii-12b2b04c8c4c8298Pharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Hawaiihttps://www.pharmaradar360.com/article/2027-step-out-walk-charlotte-9a1e7a1e11085daePharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Charlottehttps://www.pharmaradar360.com/article/bio-2026-cell-and-gene-therapy-sector-must-break-the-mold-to-thrive-4fe03b4af8563984Pharma Surgeen2026-06-22T04:53:00.000ZBIO 2026: Cell and gene therapy sector must break the mold to thrivehttps://www.pharmaradar360.com/article/sanofi-s-r-d-chief-ashrafian-to-hit-the-exit-as-new-ceo-seeks-to-fix-stuttering-306305e1e65121d6Pharma Surgeen2026-06-22T03:48:00.000ZSanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alumhttps://www.pharmaradar360.com/article/shinsa-cdx-approved-for-identifying-eligible-patients-updated-june-16-2026-54d2f1b7bc99c8c4Pharma Surgeen2026-06-22T03:00:00.000Z[SHINSA]CDx approved for identifying eligible patients (Updated June 16, 2026)https://www.pharmaradar360.com/article/shinsa-list-of-approved-drugs-april-2004-to-february-2026-36a9fdbe61938f13Pharma Surgeen2026-06-22T03:00:00.000Z[SHINSA]List of Approved Drugs: April 2004 to February 2026https://www.pharmaradar360.com/article/one-common-fat-may-fuel-type-2-diabetes-while-another-helps-fight-it-d21b2205ad875829Pharma Surgeen2026-06-22T00:25:04.000ZOne common fat may fuel type 2 diabetes while another helps fight ithttps://www.pharmaradar360.com/article/long-term-health-risks-of-e-cigarettes-after-smoking-cessation-0b5010b57e88e76cPharma Surgeen2026-06-22T00:00:00.000ZLong-term health risks of e-cigarettes after smoking cessationhttps://www.pharmaradar360.com/article/a-case-of-artificial-intelligence-enhanced-diagnostics-leading-to-heart-transpla-b78475cff8c90f71Pharma Surgeen2026-06-22T00:00:00.000ZA case of artificial intelligence-enhanced diagnostics leading to heart transplantationhttps://www.pharmaradar360.com/article/biological-aging-and-generational-shifts-in-early-onset-cancer-risk-319a99ff0f8777baPharma Surgeen2026-06-22T00:00:00.000ZBiological aging and generational shifts in early-onset cancer riskhttps://www.pharmaradar360.com/article/make-science-more-reliable-study-people-as-they-go-about-their-lives-cda2ca72bab5b884Pharma Surgeen2026-06-22T00:00:00.000ZMake science more reliable: study people as they go about their liveshttps://www.pharmaradar360.com/article/why-heritage-sites-are-at-risk-in-a-warming-world-and-how-to-save-them-66d16ddfe34c4e2aPharma Surgeen2026-06-22T00:00:00.000ZWhy heritage sites are at risk in a warming world — and how to save themhttps://www.pharmaradar360.com/article/the-first-ticking-nuclear-clocks-are-here-what-can-they-do-374eea03e8011488Pharma Surgeen2026-06-22T00:00:00.000ZThe first ticking ‘nuclear clocks’ are here — what can they do?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-88765df961c41d8cPharma Surgeen2026-06-22T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-8d3a38d9a9f2c790Pharma Surgeen2026-06-22T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-2fd7783bb395bef5Pharma Surgeen2026-06-22T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-f6fb7f3135e9649cPharma Surgeen2026-06-22T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-ecbdfd7ec8a2cb96Pharma Surgeen2026-06-22T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4d8866785078836ePharma Surgeen2026-06-22T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-21c68bd1a09f4cedPharma Surgeen2026-06-22T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4e5275bcf166f9f0Pharma Surgeen2026-06-22T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-065a224782343c4bPharma Surgeen2026-06-22T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d092fe389fffc947Pharma Surgeen2026-06-22T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-354044ca1f0a8452Pharma Surgeen2026-06-22T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-898c0eca335249d7Pharma Surgeen2026-06-22T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-5c65e15922515026Pharma Surgeen2026-06-22T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-ada682316308b8ebPharma Surgeen2026-06-22T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/nu-kraftsamlar-ki-inom-medicinsk-beredskap-113080484829c8efPharma Surgeen2026-06-22T00:00:00.000ZNu kraftsamlar KI inom medicinsk beredskaphttps://www.pharmaradar360.com/article/nobelkonferens-samlade-ledande-forskare-inom-mikrogliaforskning-079c01fb876b0f35Pharma Surgeen2026-06-22T00:00:00.000ZNobelkonferens samlade ledande forskare inom mikrogliaforskninghttps://www.pharmaradar360.com/article/stockwatch-positive-phase-iii-data-sells-investors-on-intellia-9faa5fbbb009cc4dPharma Surgeen2026-06-21T23:40:59.000ZStockWatch: Positive Phase III Data Sells Investors on Intelliahttps://www.pharmaradar360.com/article/beta-blockers-why-people-are-turning-to-an-old-drug-for-high-stress-moments-510d950959cb8a6aPharma Surgeen2026-06-21T22:35:37.000ZBeta Blockers: Why People Are Turning to an Old Drug for High-Stress Momentshttps://www.pharmaradar360.com/article/insilico-lands-heavily-backloaded-2-5b-ai-drug-discovery-deal-with-sk-biopharm-3a827a80ff016c48Pharma Surgeen2026-06-21T21:41:00.000ZInsilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharmhttps://www.pharmaradar360.com/article/definium-s-lsd-formula-produces-best-data-ever-seen-in-a-pivotal-depression-tria-e5291f0843b2a7a7Pharma Surgeen2026-06-21T19:08:00.000ZDefinium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO sayshttps://www.pharmaradar360.com/article/update-for-rounak-kumawat-69702f597482f093Pharma Surgeen2026-06-21T17:11:10.000ZUpdate for Rounak Kumawathttps://www.pharmaradar360.com/article/update-for-jitendra-narayan-3fbc7fdac3059fb3Pharma Surgeen2026-06-21T17:11:10.000ZUpdate for Jitendra Narayanhttps://www.pharmaradar360.com/article/built-different-the-case-for-specialized-humanoids-63c54db704a98463Pharma Surgeen2026-06-21T15:31:58.000ZBuilt Different: The Case for Specialized Humanoidshttps://www.pharmaradar360.com/article/long-lived-families-reveal-a-rare-genetic-clue-to-healthy-aging-d621bcebd8ce5086Pharma Surgeen2026-06-21T14:57:42.000ZLong-lived families reveal a rare genetic clue to healthy aginghttps://www.pharmaradar360.com/article/tubulin-prevents-toxic-brain-protein-clumps-linked-to-alzheimer-s-and-parkinson-ea613fc4792fea2dPharma Surgeen2026-06-21T13:08:10.000ZTubulin prevents toxic brain protein clumps linked to Alzheimer’s and Parkinson’shttps://www.pharmaradar360.com/article/yale-study-finds-nearly-half-of-older-adults-improved-with-age-6c6d331c4d824a09Pharma Surgeen2026-06-21T10:02:10.000ZYale study finds nearly half of older adults improved with agehttps://www.pharmaradar360.com/article/nhsggc-team-provides-vital-skin-cancer-support-as-demand-grows-4ea9e1b316c836fdPharma Surgeen2026-06-21T08:30:00.000ZNHSGGC team provides vital skin cancer support as demand growshttps://www.pharmaradar360.com/article/scientists-discover-neurons-must-break-their-dna-to-build-the-brain-8ed705383cda1371Pharma Surgeen2026-06-21T06:30:35.000ZScientists discover neurons must break their DNA to build the brainhttps://www.pharmaradar360.com/article/major-review-finds-vaping-likely-causes-lung-and-oral-cancer-a62ed56320212583Pharma Surgeen2026-06-21T05:26:23.000ZMajor review finds vaping likely causes lung and oral cancerhttps://www.pharmaradar360.com/article/scientists-found-a-cannabis-compound-that-relieves-pain-without-the-high-40735f2b86392634Pharma Surgeen2026-06-20T15:33:51.000ZScientists found a cannabis compound that relieves pain without the highhttps://www.pharmaradar360.com/article/this-dna-repair-gene-went-rogue-and-exposed-a-cancer-weakness-c06077b5d7503918Pharma Surgeen2026-06-20T12:27:35.000ZThis DNA repair gene went rogue and exposed a cancer weaknesshttps://www.pharmaradar360.com/article/ozempic-changed-obesity-treatment-but-experts-say-the-real-revolution-is-next-9ec9bda307a8dbfcPharma Surgeen2026-06-20T11:28:46.000ZOzempic changed obesity treatment, but experts say the real revolution is nexthttps://www.pharmaradar360.com/article/subcutaneous-versus-transvenous-implantable-cardioverter-defibrillators-in-end-s-5fdb224a651b3c6cPharma Surgeen2026-06-20T07:39:39.000ZSubcutaneous Versus Transvenous Implantable Cardioverter‐Defibrillators in End‐Stage Renal Disease: A Real‐World Studyhttps://www.pharmaradar360.com/article/focal-activations-detected-by-an-automated-mapping-system-insights-from-contrala-c41d9495cbfbd2f2Pharma Surgeen2026-06-20T07:36:52.000ZFocal Activations Detected by an Automated Mapping System: Insights From Contralateral Atrial Burst Pacinghttps://www.pharmaradar360.com/article/first-experience-with-extravascular-implantable-cardioverter-defibrillator-under-4eae81a0f251fb53Pharma Surgeen2026-06-20T07:00:00.000ZFirst Experience With Extravascular Implantable Cardioverter‐Defibrillator Under Deep Sedationhttps://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-c8c509e4442e2a86Pharma Surgeen2026-06-20T07:00:00.000ZTherapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1https://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-without-driver-alterations-asco-fa729545754d224ePharma Surgeen2026-06-20T07:00:00.000ZTherapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1https://www.pharmaradar360.com/article/lessons-from-gbm-agile-s-regorafenib-experience-in-newly-diagnosed-and-recurrent-a2691796a2c41276Pharma Surgeen2026-06-20T07:00:00.000ZLessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastomahttps://www.pharmaradar360.com/article/long-term-efficacy-and-safety-of-taletrectinib-in-patients-with-ros1-non-small-c-2d8d5b2983621c9fPharma Surgeen2026-06-20T07:00:00.000ZLong-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Studyhttps://www.pharmaradar360.com/article/reply-to-treatment-switching-and-subsequent-therapy-confound-overall-survival-es-f7b548b4462b512dPharma Surgeen2026-06-20T07:00:00.000ZReply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROShttps://www.pharmaradar360.com/article/reply-to-signal-worth-trusting-if-we-can-reproduce-it-clarifying-overall-respons-1d076353514f8771Pharma Surgeen2026-06-20T07:00:00.000ZReply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immunohttps://www.pharmaradar360.com/article/menopausal-hormone-therapy-after-breast-cancer-personalization-not-prohibition-6c7ef606352e6cd3Pharma Surgeen2026-06-20T07:00:00.000ZMenopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibitionhttps://www.pharmaradar360.com/article/cracks-in-the-estrogen-carcinogenesis-of-breast-cancer-fc65f1bac5694641Pharma Surgeen2026-06-20T07:00:00.000ZCracks in the Estrogen Carcinogenesis of Breast Cancerhttps://www.pharmaradar360.com/article/signal-worth-trusting-if-we-can-reproduce-it-clarifying-overall-response-rate-an-10c782472bb13067Pharma Surgeen2026-06-20T07:00:00.000ZSignal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immunohttps://www.pharmaradar360.com/article/multicenter-randomized-phase-ii-trial-of-olaparib-plus-radium-223-versus-radium-68cb1b45f4ed21d7Pharma Surgeen2026-06-20T07:00:00.000ZMulticenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)https://www.pharmaradar360.com/article/treatment-switching-and-subsequent-therapy-confound-overall-survival-estimates-i-0a1f9feab7c0d141Pharma Surgeen2026-06-20T07:00:00.000ZTreatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROShttps://www.pharmaradar360.com/article/expert-opinion-on-the-diagnosis-and-treatment-of-hematologic-malignancies-during-651d3c6f62e7de6cPharma Surgeen2026-06-20T07:00:00.000ZExpert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancyhttps://www.pharmaradar360.com/article/neoadjuvant-single-cycle-pembrolizumab-for-stage-i-iii-mmr-deficient-colon-cance-9b6bcc718272c052Pharma Surgeen2026-06-20T07:00:00.000ZNeoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trialhttps://www.pharmaradar360.com/article/ficerafusp-alfa-bca101-with-pembrolizumab-for-recurrent-or-metastatic-head-and-n-f47be6df5da460a3Pharma Surgeen2026-06-20T07:00:00.000ZFicerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trialhttps://www.pharmaradar360.com/article/evaluation-of-regorafenib-in-newly-diagnosed-and-recurrent-glioblastoma-gbm-agil-30741e411920454bPharma Surgeen2026-06-20T07:00:00.000ZEvaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trialhttps://www.pharmaradar360.com/article/malignant-adult-ovarian-germ-cell-tumors-an-international-multicenter-study-to-i-ff91fb7f41cde9a0Pharma Surgeen2026-06-20T07:00:00.000ZMalignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyondhttps://www.pharmaradar360.com/article/glucocorticoid-and-mitophagy-signaling-based-molecular-subtyping-reveals-hmga1-a-c72453d7c1024a5aPharma Surgeen2026-06-20T00:00:00.000ZGlucocorticoid and mitophagy signaling–based molecular subtyping reveals HMGA1 as a prognostic and immunotherapy biomarker in lung adenocarcinomahttps://www.pharmaradar360.com/article/sgi-7079-as-a-novel-type-i-flt3-inhibitor-overcomes-resistance-to-gilteritinib-a-b9628db115a3379fPharma Surgeen2026-06-20T00:00:00.000ZSGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemiahttps://www.pharmaradar360.com/article/hmgb3-facilitates-malignant-phenotype-of-esophageal-carcinoma-via-histone-lactyl-c0c1aa6f269a7e73Pharma Surgeen2026-06-20T00:00:00.000ZHMGB3 facilitates malignant phenotype of esophageal carcinoma via histone lactylation- and Wnt/β-catenin-dependent transcription activation of c-mychttps://www.pharmaradar360.com/article/clinical-responses-to-trastuzumab-deruxtecan-in-molecularly-defined-ependymoma-c573925998b5e35cPharma Surgeen2026-06-20T00:00:00.000ZClinical responses to trastuzumab deruxtecan in molecularly defined ependymomahttps://www.pharmaradar360.com/article/la-ricerca-di-policlinico-di-milano-universita-degli-studi-di-milano-protagonist-c238d3c23fd4bef3Pharma Surgeen2026-06-19T22:24:00.000ZLa ricerca di Policlinico di Milano-Università degli Studi di Milano protagonista all’European Hematology Associationhttps://www.pharmaradar360.com/article/newsletter-dottoressav-peli-brufoli-e-bilancia-bloccata-no-non-dipende-da-te-si-7f54450e9e0a5559Pharma Surgeen2026-06-19T21:55:00.000Z#NEWSLETTER. DottoressaV - Peli, brufoli e bilancia bloccata? No, non dipende da te, si chiama PMOShttps://www.pharmaradar360.com/article/alfredo-gaete-asume-la-direccion-del-campus-villarrica-con-foco-en-el-territorio-63ecc5aacf196877Pharma Surgeen2026-06-19T19:11:55.000ZAlfredo Gaete asume la dirección del campus Villarrica con foco en el territoriohttps://www.pharmaradar360.com/article/rad-tech-society-establishes-scholarships-in-memory-of-2-influential-members-ac756e194b4d3bc3Pharma Surgeen2026-06-19T19:03:35.000ZRad tech society establishes scholarships in memory of 2 influential membershttps://www.pharmaradar360.com/article/asco-2026-next-generation-immunotherapies-16e02b4d6d688f57Pharma Surgeen2026-06-19T18:44:28.000ZASCO 2026: Next-Generation Immunotherapieshttps://www.pharmaradar360.com/article/art-show-features-work-from-45-student-artists-34b172110e0431caPharma Surgeen2026-06-19T17:52:20.000ZArt show features work from 45 student artistshttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-press-release-pursuant-to-article-38-paragraph-8637762fcce8990fPharma Surgeen2026-06-19T17:49:09.000ZOn behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 38, paragraph 1, of the Issuers’ Regulation – Suspension of the review periodhttps://www.pharmaradar360.com/article/fda-clears-radnet-s-ai-powered-breast-arterial-calcification-solution-39d51c1c96ad1c26Pharma Surgeen2026-06-19T17:44:23.000ZFDA clears RadNet's AI-powered breast arterial calcification solutionhttps://www.pharmaradar360.com/article/college-world-series-means-special-father-s-day-for-carolina-coach-family-1a4fe4c6c037eedcPharma Surgeen2026-06-19T17:34:58.000ZCollege World Series means special Father’s Day for Carolina coach, familyhttps://www.pharmaradar360.com/article/this-fan-worked-for-crawdads-panthers-and-bulls-d3bf19df14428f8fPharma Surgeen2026-06-19T17:34:41.000ZThis fan worked for Crawdads, Panthers and Bullshttps://www.pharmaradar360.com/article/resultados-del-ranking-qs-destacan-fortalecimiento-de-la-experiencia-formativa-e-57330615198b2eeePharma Surgeen2026-06-19T17:26:16.000ZResultados del ranking QS destacan fortalecimiento de la experiencia formativa en la UChttps://www.pharmaradar360.com/article/mmi-partners-with-joslyn-castle-to-staff-carriage-house-cafe-6fdc76ff349f30caPharma Surgeen2026-06-19T16:58:57.000ZMMI partners with Joslyn Castle to staff Carriage House Cafehttps://www.pharmaradar360.com/article/anmat-fortalece-su-capacidad-de-referencia-regional-en-el-control-de-vacunas-ant-dacdc46d441bbe86Pharma Surgeen2026-06-19T16:48:38.000ZANMAT fortalece su capacidad de referencia regional en el control de vacunas antigripaleshttps://www.pharmaradar360.com/article/garden-walk-draws-thousands-for-good-cause-6be9e41e5e38719bPharma Surgeen2026-06-19T16:46:19.000ZGarden Walk draws thousands for good causehttps://www.pharmaradar360.com/article/medhealth-outlook-altasciences-drug-development-that-is-faster-by-design-28f42083774a4d7bPharma Surgeen2026-06-19T16:38:12.000ZMedhealth Outlook: Altasciences - Drug Development That is Faster by Designhttps://www.pharmaradar360.com/article/mmi-voices-occupational-therapy-summer-camps-offer-fun-friendship-and-skill-buil-28edb7421eea5869Pharma Surgeen2026-06-19T16:19:37.000ZMMI Voices: Occupational therapy summer camps offer fun, friendship and skill buildinghttps://www.pharmaradar360.com/article/pharmaceutical-executive-daily-fda-advisory-committee-votes-unanimously-in-favor-e4933408b042bd66Pharma Surgeen2026-06-19T16:04:37.000ZPharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010https://www.pharmaradar360.com/article/la-unlp-consolida-su-lugar-a-nivel-nacional-y-se-mantiene-entre-las-mejores-del-7ec125b6acedd896Pharma Surgeen2026-06-19T15:50:51.000ZLa UNLP consolida su lugar a nivel nacional y se mantiene entre las mejores del mundo en el ranking QShttps://www.pharmaradar360.com/article/homenaje-a-la-bandera-en-los-jardines-del-rectorado-8326c312b5ac6204Pharma Surgeen2026-06-19T15:50:11.000ZHomenaje a la Bandera en los jardines del Rectoradohttps://www.pharmaradar360.com/article/signing-in-to-mychart-with-your-nhs-login-55dd9efea79e578ePharma Surgeen2026-06-19T15:49:45.000ZSigning in to MyChart with your NHS loginhttps://www.pharmaradar360.com/article/ai-readiness-in-pharma-getting-the-foundation-right-709c81fe69ec3e32Pharma Surgeen2026-06-19T15:20:37.000ZAI Readiness in Pharma – Getting the Foundation Righthttps://www.pharmaradar360.com/article/prof-dr-matthias-guckenberger-ubergibt-estro-prasidentschaft-e4ade8f3e426a8b8Pharma Surgeen2026-06-19T15:01:40.000ZProf. Dr. Matthias Guckenberger übergibt ESTRO-Präsidentschafthttps://www.pharmaradar360.com/article/wildlife-in-chornobyl-is-changing-its-behaviour-during-russian-invasion-d1c53a24c39be9faPharma Surgeen2026-06-19T14:37:34.000ZWildlife in Chornobyl is changing its behaviour during Russian invasionhttps://www.pharmaradar360.com/article/congressman-proposes-draft-legislation-to-accelerate-us-clinical-trials-d363bf1ab8cd0470Pharma Surgeen2026-06-19T14:32:26.000ZCongressman proposes draft legislation to accelerate US clinical trialshttps://www.pharmaradar360.com/article/qs-world-university-rankings-2027-the-university-of-freiburg-ranks-among-the-top-95fe9d76619c26fePharma Surgeen2026-06-19T14:30:04.000ZQS World University Rankings 2027: The University of Freiburg ranks among the top 10 nationally across several indicatorshttps://www.pharmaradar360.com/article/pharma-funding-roudup-kardigan-announces-400-million-initial-ipo-campfield-launc-f87fd6eaacec60bdPharma Surgeen2026-06-19T14:09:52.000ZPharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series Ahttps://www.pharmaradar360.com/article/think-you-re-eating-healthy-you-may-be-missing-this-heart-protecting-nutrient-0f351bb3f1252353Pharma Surgeen2026-06-19T13:56:05.000ZThink you're eating healthy? You may be missing this heart-protecting nutrienthttps://www.pharmaradar360.com/article/eye-opening-study-highlights-connection-between-hpv-and-uveitis-641f5b6f51f2f1a6Pharma Surgeen2026-06-19T13:54:42.000ZEye-opening study highlights connection between HPV and uveitishttps://www.pharmaradar360.com/article/fda-advisory-committee-votes-unanimously-in-favor-of-the-benefit-risk-profile-of-7172dd078f9e2e5aPharma Surgeen2026-06-19T13:43:05.000ZFDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010https://www.pharmaradar360.com/article/vinculaciones-municipios-unlp-2026-48704d87014cfb42Pharma Surgeen2026-06-19T13:30:47.000ZVINCULACIONES MUNICIPIOS – UNLP 2026